Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

What is required to advance data ethics, data sharing, and Open Science across LMICs

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Genomic testing: Australian model for unlocking the potential of precision oncology for patients and health systems

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Cancer survivors' stories: An African perspective

ESMO 2022: Breast and ovarian trial analysis

Neoadjuvant immunotherapy improves outlook in high-risk melanoma